Nov 2, 4:11 PM ET
The Clorox Company reported its first-quarter fiscal 2027 results, showing a 33% increase in net sales to $1.91 billion and a diluted net earnings per share of $1.39. While maintaining its fiscal year 2027 full-year net sales and adjusted EPS ranges, the company expects adjusted EPS results closer to the low end due to higher inflationary pressures and commodity costs.
- Net sales increased 33% to $1.91 billion, with organic sales up 18%.
- Diluted EPS increased 114% to $1.39 compared to $0.65 in the year-ago quarter.
- Adjusted EPS increased 82% to $1.55 compared to $0.85 in the year-ago quarter.
- Full-year fiscal 2027 diluted EPS is expected to be between $5.41 and $5.71, with adjusted EPS expected between $5.70 and $6.00.
Read the filing on SEC.gov ↗
Oct 29, 7:05 AM ET
The Clorox Company's board appointed Fabian Garcia, currently president of Unilever Personal Care, as chief executive officer effective January 5, 2027. Linda Rendle steps down as CEO and chair on that date and will serve as a senior advisor through April 2, 2027, while Matthew Shattock becomes independent chair. The filing lists Garcia's offer terms, including a $100,000 base salary and an $11,000,000 sign-on RSU award, and the company's first-quarter fiscal 2027 earnings are scheduled for November 2.
- Fabian Garcia appointed CEO effective January 5, 2027; he will also join the board
- Linda Rendle steps down as CEO and director on January 5, 2027, and advises through April 2, 2027
- Matthew Shattock to become independent chair, with a $225,000 chair retainer
- Garcia's offer letter includes a $100,000 base salary, $2,000,000 target annual bonus and $11,000,000 one-time sign-on RSU award
Read the filing on SEC.gov ↗
Aug 3, 4:12 PM ET
Clorox reported fourth-quarter and fiscal 2026 results on August 3, 2026, with net sales down 2% to $1.95 billion and diluted EPS down 50% to $1.34, as lapping ERP-related shipments and GOJO acquisition costs weighed on results. For fiscal 2027 the company expects net sales to rise 13% to 14%, including about 9.5 points from the GOJO acquisition, and diluted EPS of $5.41 to $5.71, while describing the operating environment as challenging.
- Q4 net sales decreased 2% to $1.95 billion; GOJO added about 10 points, while organic sales decreased 13%.
- Q4 diluted EPS was $1.34 versus $2.68 a year earlier; adjusted EPS was $1.66 versus $2.87.
- Fiscal 2026 net sales fell 5% to $6.72 billion and diluted EPS fell 26% to $4.81; operating cash flow was $612 million versus $981 million.
- Fiscal 2027 outlook: adjusted EPS of $5.70 to $6.00, and gross margin of about 42%.
Read the filing on SEC.gov ↗
Jun 17, 4:15 PM ET
Clorox appointed Chris Hyder as executive vice president and chief operating officer and Nina Barton as executive vice president and chief growth and strategy officer, both effective June 17, 2026, as part of a simplified operating structure. The company also said its board is running a search for a new CEO, which it first announced on May 28.
- Chris Hyder named EVP and chief operating officer effective June 17, 2026, with base salary raised to $800,000 and short-term incentive target raised from 90% to 100%
- Hyder to receive restricted stock units with an aggregate fair value of $4,000,000, vesting in three years
- Nina Barton moves to EVP and chief growth and strategy officer; commercial functions will report to her role
- Board is undertaking a comprehensive search with a leading firm for a new CEO, as announced May 28
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.